Results 41 to 50 of about 6,346 (180)
Treatment of Ocular Myasthenia Gravis
Myasthenia gravis is a relatively common neuromuscular disorder, with ocular myasthenia gravis being a subset defined as myasthenia gravis limited to the orbicularis, levator, and extraocular muscles. Patients with ocular myasthenia gravis can have disabling diplopia or functional blindness from ptosis and in most cases treatment is required.
openaire +2 more sources
Presynaptic Congenital Myasthenic Syndromes
ABSTRACT Presynaptic congenital myasthenic syndromes (CMS) encompass a large number of rare neurologic disorders caused by impaired release of acetylcholine (ACh) from motor nerve terminals. There are two main groups of presynaptic CMS: one in which the amount of ACh in synaptic vesicles (SV) is diminished and another in which the mechanism of synaptic
Ricardo A. Maselli
wiley +1 more source
Introduction The autoimmune disease myasthenia gravis can mimic a variety of neurological disorders leading to a delay in diagnosis and treatment. In the older population, due to confusion with signs of the ageing process or comorbidities due to ageing ...
Avinash Chandra, Basant Pant
doaj +1 more source
ABSTRACT Seronegative myasthenia gravis (SNMG) is characterized by the absence of detectable autoantibodies against known MG targets, despite clinical and electrophysiological evidence of a postsynaptic neuromuscular junction disorder. The aim of this systematic review was to better define clinical features, diagnostic clues and treatment outcome of ...
Massimiliano Ugo Verza +6 more
wiley +1 more source
Thymic mass in an elderly male patient with myasthenia gravis: A rare presentation
Myasthenia gravis is an acquired neuromuscular disorder characterized by weakness of the extra-ocular muscles, which progresses to generalized weakness of the voluntary muscles and fatigability.
Anshul Sood, MBBS +4 more
doaj +1 more source
Treatment Preferences of Patients With Myasthenia Gravis: A Qualitative Study
ABSTRACT Introduction/Aims The burden of myasthenia gravis (MG) is often underestimated, and studies usually focus on the symptom burden. However, treatment‐related adverse events also contribute to patients' burdens and affect their treatment decisions.
Meg Mendoza +6 more
wiley +1 more source
IgG Subclass (IgG1‐4) and IgA Autoantibody Profiles Against Muscle‐Specific Kinase in a Greek Cohort
ABSTRACT Introduction/Aims Muscle‐specific kinase myasthenia gravis (MuSK‐MG) is an autoimmune neuromuscular disorder predominantly mediated by IgG4 autoantibodies disrupting MuSK signaling. The contribution of other isotypes remains incompletely defined. We characterized the serological profile of a Greek cohort of MuSK‐MG patients.
Sofia‐Natsοuko Gkotzamani +22 more
wiley +1 more source
ABSTRACT Thymoma is the most common tumor of the anterior mediastinum. Approximately 20%–30% of patients with a thymoma develop myasthenia gravis (MG), and an additional one third may possess positive acetylcholine receptor (AChR) antibodies without MG.
Benjamin Claytor +5 more
wiley +1 more source
ABSTRACT Urinary dysfunction has been reported in association with myasthenic syndromes, including myasthenia gravis (MG), Lambert–Eaton myasthenic syndrome (LEMS), and congenital myasthenic syndromes (CMS), but evidence regarding its prevalence, clinical impact, pathophysiology, and management remains limited.
Julia M. Augustin +13 more
wiley +1 more source
The evaluation of approaches to the treatment of myasthenia gravis.
Myasthenia gravis is a relatively rare autoimmune disease with an undetermined aetiology which affects neuromuscular junctions. Currently, the following approaches to the treatment of myasthenia gravis are mainly distinguished: symptomatic treatment with
O. I. Kalbus +4 more
doaj +1 more source

